Pregabalin patents have largely expired, allowing for the availability of generic versions.
When Does Pregabalin Go Off-Patent?
The primary patents for pregabalin, originally marketed as Lyrica by Pfizer, began expiring around 2018 in various regions. This expiration opened the door for generic manufacturers to produce and market their own versions of the drug. For example, U.S. patents for pregabalin expired between 2018 and 2019 [1].
Who Makes Generic Pregabalin?
Numerous pharmaceutical companies worldwide now manufacture generic pregabalin. These include companies like Teva Pharmaceuticals, Mylan, and Aurobindo Pharma, among many others [2]. The availability of generics has led to increased competition and lower prices for the medication.
How Does Generic Pregabalin Compare to Lyrica?
Generic pregabalin products are bioequivalent to the brand-name Lyrica. This means they contain the same active ingredient, are administered in the same dosage form, and have the same strength and route of administration. Regulatory bodies like the U.S. Food and Drug Administration (FDA) require generic drugs to demonstrate bioequivalence before they can be approved [3].
Why is Patent Expiration Important for Patients?
Patent expiration is crucial for patients as it typically leads to a significant decrease in the cost of medication. Once exclusive rights expire, multiple manufacturers can produce the drug, driving down prices through competition. This increased affordability makes essential treatments more accessible to a wider patient population.
What Are the Uses of Pregabalin?
Pregabalin is a medication prescribed for several conditions, including neuropathic pain, epilepsy, fibromyalgia, and generalized anxiety disorder [4]. Its mechanism of action involves binding to alpha-2-delta (α2δ) subunits of voltage-gated calcium channels, which modulates neurotransmitter release in the central nervous system [5].
Are There Any Remaining Pregabalin Patents?
While the main patents have expired, there could be secondary patents related to specific formulations, manufacturing processes, or new uses for pregabalin that may still be in effect. However, these are unlikely to prevent the widespread availability of generic versions for established indications [1].
Sources:
[1] DrugPatentWatch.com https://drugpatentwatch.com/
[2] https://www.drugs.com/availability/pregabalin.html
[3] https://www.fda.gov/drugs/generic-drugs/what-generic-drugs-are
[4] https://www.nhs.uk/medicines/pregabalin/
[5] https://pubmed.ncbi.nlm.nih.gov/15613517/